vTv Therapeutics Inc. entered into Second Amendment to License Agreement with Newsoara Biopharma Co., Ltd. valued at $20 million upfront fee, up to $50 million in development milestones, $65 million in sales-related m (effective 2026-01-30).
“On January 30, 2026, vTv Therapeutics LLC (“vTv LLC” or the "Company"), a subsidiary of vTv Therapeutics Inc., entered into the Second Amendment to License Agreement with Newsoara Biopharma Co., Ltd. (“Newsoara”) (the “Second Amendment”) to amend the License Agreement previously entered into between vTv LLC and Newsoara on May 31, 2018 (the “Original Agreement”).”
Governance Changes
vTv Therapeutics Inc.: Reduced quorum requirement for stockholder meetings to 33.4% (effective 2025-12-19).
“On December 19, 2025, the Board of Directors of vTv Therapeutics Inc. (the Company) amended Section 2.8 of Article II of the Company’s Second Amended and Restated By-Laws to reduce the quorum requirement for any meeting of stockholders to 33.4%.”
Michael Tung was appointed as executive vice president and chief financial officer at vTv Therapeutics Inc..
“On May 19, 2025, vTv Therapeutics Inc. (the “Company”) announced that the Company has appointed Michael Tung as executive vice president and chief financial officer of the Company, effective as of May 19, 2025.”
Barry K. Brown was appointed as interim principal financial officer at vTv Therapeutics Inc..
“On April 11, 2025, the Board of Directors of vTv Therapeutics Inc. (the “Company”) appointed Barry K. Brown, age 64, as interim principal financial officer effective immediately.”
Steven Tuch resigned as Executive Vice President and Chief Financial Officer at vTv Therapeutics Inc..
“On February 24, 2025, Steven Tuch, Executive Vice President and Chief Financial Officer of vTv Therapeutics Inc. (the "Company"), informed the Company of his intention to resign from his position effective March 21, 2025.”
Earnings Releases
vTv Therapeutics Inc. reported financial results for the first quarter ended March 31, 2024.
“On May 9, 2024, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal period ended March 31, 2024.”
Howard Weiner resigned as director at vTv Therapeutics Inc..
“John Fry and Howard Weiner resigned from their director roles effective upon the filing of the 2023 Annual Report.”
John Fry resigned as director at vTv Therapeutics Inc..
“John Fry and Howard Weiner resigned from their director roles effective upon the filing of the 2023 Annual Report.”
Anne Phillips was elected as director at vTv Therapeutics Inc..
“On March 12, 2024, Anne Phillips was elected as director of vTv Therapeutics, Inc. (the “Company”), effective and contingent on the filing of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, which occurred on March 13, 2024 (the “2023 Annual Report”).”
Earnings Releases
vTv Therapeutics Inc. reported financial results for the fiscal year ended December 31, 2023.
“On March 13, 2024, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal year ended December 31, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.